Chinese Guideline for Lipid Management (Primary Care Version 2024)

doi:10.12114/j.issn.1007-9572.2024.0005

Abstract

Abstract:

Low-density lipoprotein cholesterol (LDL-C) is a pathogenic risk factor for atherosclerotic cardiovascular disease (ASCVD). In recent decades, the prevalence of dyslipidemia in the Chinese population increases continuously, it is urgent to improve blood lipid management in China. It is particularly important to carry out standardized blood lipid management at primary healthcare institutions. The Chinese Guideline for Lipid Management (Primary Care Version 2024) concisely recommends that LDL-C should be the preferred intervention target in lipid management, and the target values of LDL-C should be determined based on ASCVD risk stratification. The present guideline recommends to use moderate-intensity statins at the beginning of treatment on the basis of lifestyle intervention. If the LDL-C target level can not be reached, other lipid-lowering drugs like cholesterol absorption inhibitors or (and) proprotein convertase subtilisin/kexin type 9 inhibitors should be jointly used for the purpose of reaching the target value. The present guideline also provides blood lipid management strategies for special populations. We aim to provide guidance for primary healthcare professionals to carry out blood lipid management, and comprehensively improve their ability on blood lipid management, and thereby improve the primary and secondary prevention of ASCVD in China.

Key words: Atherosclerosis, Cardiovascular disease, Blood lipid management, Low-density lipoprotein cholesterol, Primary healthcare institution

摘要： 低密度脂蛋白胆固醇（LDL-C）是动脉粥样硬化性心血管疾病（ASCVD）的致病性危险因素。近几十年来，中国人群的血脂异常患病率不断升高，血脂管理刻不容缓，在基层开展血脂规范管理尤为重要。《中国血脂管理指南（基层版2024年）》简明地推荐LDL-C作为血脂干预的首要靶点，以ASCVD危险分层确定其目标值；推荐在生活方式干预的基础上，以中等强度他汀类药物作为起始药物治疗，必要时联用胆固醇吸收抑制剂或/和前蛋白转化酶枯草溶菌素9抑制剂的达标策略；并就常见特殊人群的血脂管理策略进行了推荐。本指南旨在为基层医生开展血脂管理提供指导，全面提升基层医生的血脂管理水平，推进ASCVD的一级和二级预防工作。

关键词: 动脉粥样硬化, 心血管疾病, 血脂管理, 低密度脂蛋白胆固醇, 基层

CLC Number:

R 54

Joint Committee on the Chinese Guidelines for Lipid Management. Chinese Guideline for Lipid Management (Primary Care Version 2024)[J]. Chinese General Practice, 2024, 27(20): 2429-2436. DOI: 10.12114/j.issn.1007-9572.2024.0005.
中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（基层版2024年）[J]. 中国全科医学, 2024, 27(20): 2429-2436. DOI: 10.12114/j.issn.1007-9572.2024.0005.

Figures/Tables 9

References 34

[1]	国家心血管病中心. 中国心血管健康与疾病报告2021[M]. 北京：科学出版社，2022.
[2]	FERENCE B A, GINSBERG H N, GRAHAM I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic，epidemiologic，and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J，2017，38(32):2459-2472. DOI：10.1093/eurheartj/ehx144.
[3]	国家卫生健康委员会疾病预防控制局. 中国居民营养与慢性病状况报告2015[M]. 北京：人民卫生出版社，2015.
[4]	中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（2023年）[J]. 中国循环杂志，2023，38(3):237-271. DOI：10.3969/j.issn.1000-3614.2023.03.001.
[5]	Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease：meta-analysis of individual data from 27 randomised trials[J]. Lancet，2012，380(9841):581-590. DOI：10.1016/S0140-6736(12)60367-5.
[6]	Cholesterol Treatment Trialists Collaboration. Efficacy and safety of LDL-lowering therapy among men and women：meta-analysis of individual data from 174 000 participants in 27 randomised trials[J]. Lancet，2015，385(9976):1397-1405. DOI：10.1016/S0140-6736(14)61368-4.
[7]	YUSUF S, BOSCH J, DAGENAIS G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease[J]. N Engl J Med，2016，374(21):2021-2031. DOI：10.1056/NEJMoa1600176.
[8]	RIDKER P M, MORA S, ROSE L, et al. Percent reduction in LDL cholesterol following high-intensity statin therapy：potential implications for guidelines and for the prescription of emerging lipid-lowering agents[J]. Eur Heart J，2016，37(17):1373-1379. DOI：10.1093/eurheartj/ehw046.
[9]	BANGALORE S, FAYYAD R, KASTELEIN J J, et al. 2013 cholesterol guidelines revisited：percent LDL cholesterol reduction or attained LDL cholesterol level or both for prognosis？[J]. Am J Med，2016，129(4):384-391. DOI：10.1016/j.amjmed.2015.10.024.
[10]	SCHWARTZ G G, STEG P G, SZAREK M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med，2018，379(22):2097-2107. DOI：10.1056/NEJMoa1801174.
[11]	ZHONG V W, VAN HORN L, CORNELIS M C, et al. Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality[J]. JAMA，2019，321(11):1081-1095. DOI：10.1001/jama.2019.1572.
[12]	GINSBERG H N, KARMALLY W, SIDDIQUI M, et al. A dose-response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young men[J]. Arterioscler Thromb，1994，14(4):576-586. DOI：10.1161/01.atv.14.4.576.
[13]	GINSBERG H N, KARMALLY W, SIDDIQUI M, et al. Increases in dietary cholesterol are associated with modest increases in both LDL and HDL cholesterol in healthy young women[J]. Arterioscler Thromb Vasc Biol，1995，15(2):169-178. DOI：10.1161/01.atv.15.2.169.
[14]	MOZAFFARIAN D, MICHA R, WALLACE S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat：a systematic review and meta-analysis of randomized controlled trials[J]. PLoS Med，2010，7(3):e1000252. DOI：10.1371/journal.pmed.1000252.
[15]	KIM B K, HONG S J, LEE Y J, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease （RACING）：a randomised，open-label，non-inferiority trial[J]. Lancet，2022，400(10349):380-390. DOI：10.1016/S0140-6736(22)00916-3.
[16]	CHRISTIAN J B, ARONDEKAR B, BUYSMAN E K, et al. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia[J]. J Clin Lipidol，2012，6(5):450-461. DOI：10.1016/j.jacl.2012.08.007.
[17]	BHATT D L, STEG P G, MILLER M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia[J]. N Engl J Med，2019，380(1):11-22. DOI：10.1056/NEJMoa1812792.
[18]	YOKOYAMA M, ORIGASA H, MATSUZAKI M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients （JELIS）：a randomised open-label，blinded endpoint analysis[J]. Lancet，2007，369(9567):1090-1098. DOI：10.1016/S0140-6736(07)60527-3.
[19]	KEECH A, SIMES R J, BARTER P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus（the FIELD study）：randomised controlled trial[J]. Lancet，2005，366(9500):1849-1861. DOI：10.1016/S0140-6736(05)67667-2.
[20]	Accord Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus[J]. N Engl J Med，2010，362(17):1563-1574. DOI：10.1056/NEJMoa1001282.
[21]	CANNON C P, BLAZING M A, GIUGLIANO R P, et al. Ezetimibe added to statin therapy after acute coronary syndromes[J]. N Engl J Med，2015，372(25):2387-2397. DOI：10.1056/NEJMoa1410489.
[22]	LIAO J W, WANG X, LI Z Y, et al. Pharmacokinetic study of oral ¹⁴C-radiolabeled hyzetimibe，A new cholesterol absorption inhibitor[J]. Front Pharmacol，2021，12:665372. DOI：10.3389/fphar.2021.665372.
[23]	O'DONOGHUE M L, GIUGLIANO R P, WIVIOTT S D, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease[J]. Circulation，2022，146(15):1109-1119. DOI：10.1161/CIRCULATIONAHA.122.061620.
[24]	QI L T, LIU D X, QU Y L, et al. Tafolecimab in Chinese patients with hypercholesterolemia（CREDIT-4）：a randomized，double-blind，placebo-controlled phase 3 trial[J]. JACC Asia，2023，3(4):636-645. DOI：10.1016/j.jacasi.2023.04.011.
[25]	FITZGERALD K, WHITE S, BORODOVSKY A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med，2017，376(1):41-51. DOI：10.1056/NEJMoa1609243.
[26]	SABATINE M S, GIUGLIANO R P, KEECH A C, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med，2017，376(18):1713-1722. DOI：10.1056/NEJMoa1615664.
[27]	Cholesterol Treatment Trialists Collaborators. Efficacy of cholesterol-lowering therapy in 18，686 people with diabetes in 14 randomised trials of statins：a meta-analysis[J]. Lancet，2008，371(9607):117-125. DOI：10.1016/S0140-6736(08)60104-X.
[28]	Cholesterol Treatment Trialists Collaboration. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens：a meta-analysis of individual participant data from 28 randomised trials[J]. Lancet Diabetes Endocrinol，2016，4(10):829-839. DOI：10.1016/S2213-8587(16)30156-5.
[29]	WANNER C, KRANE V, MÄRZ W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis[J]. N Engl J Med，2005，353(3):238-248.
[30]	FELLSTRÖM B C, JARDINE A G, SCHMIEDER R E, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis[J]. N Engl J Med，2009，360(14):1395-1407. DOI：10.1056/NEJMoa0810177.
[31]	MYCHALECKYJ J C, CRAVEN T, NAYAK U, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants[J]. Diabetes Care，2012，35(5):1008-1014. DOI：10.2337/dc11-1811.
[32]	LINZ P E, LOVATO L C, BYINGTON R P, et al. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes：the ACCORD Lipid Trial[J]. Diabetes Care，2014，37(3):686-693. DOI：10.2337/dc13-0790.
[33]	AMARENCO P, LABREUCHE J. Lipid management in the prevention of stroke：review and updated meta-analysis of statins for stroke prevention[J]. Lancet Neurol，2009，8(5):453-463. DOI：10.1016/S1474-4422(09)70058-4.
[34]	AMARENCO P, BOGOUSSLAVSKY J, CALLAHAN A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack[J]. N Engl J Med，2006，355(6):549-559. DOI：10.1056/NEJMoa061894.

分类	TC	LDL-C	HDL-C	TG	非HDL-C
理想水平	—	<2.6	—	—	<3.4
合适水平	<5.2	<3.4	—	<1.7	<4.1
边缘升高	≥5.2且<6.2	≥3.4且<4.1	—	≥1.7且<2.3	≥4.1且<4.9
升高	≥6.2	≥4.1	—	≥2.3	≥4.9
降低	—	—	<1.0	—	—

分类	TC	LDL-C	HDL-C	TG	非HDL-C
理想水平	—	<2.6	—	—	<3.4
合适水平	<5.2	<3.4	—	<1.7	<4.1
边缘升高	≥5.2且<6.2	≥3.4且<4.1	—	≥1.7且<2.3	≥4.1且<4.9
升高	≥6.2	≥4.1	—	≥2.3	≥4.9
降低	—	—	<1.0	—	—

ASCVD风险等级	LDL-C推荐目标值（mmol/L）
低危^a	<3.4^[5]
中、高危^a	<2.6^[6,7]
极高危	<1.8且较基线降低幅度>50%^[8,9,10]
超高危	<1.4且较基线降低幅度>50%^[8,9,10]

ASCVD风险等级	LDL-C推荐目标值（mmol/L）
低危^a	<3.4^[5]
中、高危^a	<2.6^[6,7]
极高危	<1.8且较基线降低幅度>50%^[8,9,10]
超高危	<1.4且较基线降低幅度>50%^[8,9,10]

降胆固醇强度	药物及其剂量
高强度（每日剂量可降低LDL-C≥50%）	阿托伐他汀40~80 mg
高强度（每日剂量可降低LDL-C≥50%）	瑞舒伐他汀20 mg
中等强度（每日剂量可降低LDL-C 25%~<50%）	阿托伐他汀10~20 mg
	瑞舒伐他汀5~10 mg
	氟伐他汀80 mg
	洛伐他汀40 mg
	匹伐他汀1~4 mg
	普伐他汀40 mg
	辛伐他汀20~40 mg
	血脂康1.2 g